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9Summary 
Background: Limited data exist on thrombophilia and the risk of pregnancy-related 
venous thrombosis (VT), and there are no information on differential risk factors for 
pregnancy-related pulmonary embolism (PE) and deep vein thrombosis (DVT).
Objectives: To investigate whether hemostatic parameters known to be risk factors for 
VT in the general population were associated with pregnancy-related VT and whether 
these risk factors were differentially associated with the risk of PE and DVT. 
Methods: Blood samples were collected from a total of 313 cases with objectively 
verified first time VT and 353 controls with no history of VT originating from a source 
population of 613,232 pregnancies. 
Results: Factor (f)VIII, normalized endogenous thrombin potential (n-ETP) and D-
dimer values >90th percentiles were independent risk factors for pregnancy-related VT;
adjusted ORs (aORs) 1.7 (95% confidence interval (CI) 1.1-2.8), 1.8 (95% CI 1.1-3.0)
and 2.1 (95% CI 1.3-3.3), respectively. Reduced sensitivity to activated protein C (aPC), 
expressed as elevated normalized aPC sensitivity ratio (n-aPC-sr), was a risk factor for 
pregnancy-related VT in non-carriers of F5 rs6025 polymorphism (commonly known as 
factor V Leiden), aORs for VT for n-aPC-sr in the 4th quartile as compared with 
n-aPC-sr  the 4th quartile was 2.6 (95% CI 1.7-4.0). Analysing only carriers of factor V 
Leiden the risk of VT increased, although not statistical significant, with higher n-aPC-
sr, indicating a relation between an aPC resistance phenotype and risk of VT. The risk 
for PE as compared with controls was more than doubled in women with fIX >90th
percentile; aOR 2.4 (95% CI 1.1-5.0) and three times increased in women with free 
protein S (PS) antigen  65%; aOR 3.1 (95% CI 1.3-7.2). Carriers of factor V Leiden,
and non-carriers of factor V Leiden with n-aPC-sr in the 4th quartile had increased risk 
of DVT as compared with controls; OR 7.7 (95% CI 4.7-12.7) and aOR 3.3 (95% CI 
2.1-5.2), respectively. 9 cases and none controls were positive for at least two 
antiphosholipid antibodies (APAs) (multi-positive). Excluding women with IgM 
antibodies, 7 cases were still APA multi-positive.
Conclusions: Elevated levels of fVIII, n-ETP, D-dimer and reduced sensitivity to aPC in 
absence of factor V Leiden were independent risk factors for pregnancy-related VT.
APA multi-positivity was strongly associated with pregnancy-related VT. High levels of 
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fIX and low levels of free PS antigen was associated with increased risk of PE, and the 
risk of DVT was increased in women with reduced sensitivity to aPC in absence of 
factor V Leiden, and in carriers of factor V Leiden. Our data substantiate the hypothesis 
of differential pathophysiology between DVT and PE. 
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1. Introduction 
1.1. Hemostasis and coagulation 
The hemostatic system maintains blood in a fluid state under normal conditions, but
responds to vessel injury by rapid formation of a clot. Hemostasis is commonly 
described as primary hemostasis and secondary hemostasis. Primary hemostasis
describes the process which begins immediately after vascular damage, and is 
characterized by vasoconstriction, and platelet activation, adhesion and aggregation, and 
culminates in the formation of a platelet plug. Secondary hemostasis concerns blood 
coagulation, thrombin generation, fibrin clot formation and fibrin dissolution. 
In the early days, studying plasmas from patients with bleeding disorders was of vital 
importance for understanding the coagulation system. In 1947 Paul Owren, a Norwegian 
physician and scientist, described factor V deficiency1. In 1964 the “waterfall” or a 
“cascade” model of coagulation was proposed by two groups2;3. According to this model
coagulation proceeded in a series of proteolytic reactions. Furthermore, the coagulation 
cascade was divided into two separate pathways; the intrinsic (contact) and the extrinsic
(or tissue factor - TF) pathways, both converting into the common pathway (Figure 1).
Figure 1. The extrinsic and intrinsic pathways as originally proposed by Macfarlane3
and Davie and Ratnoff4 in 1964. 
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In 1977 Osterud and Rapaport showed that the coagulation factor (f) VII(a)/TF complex 
beyond activation of fX also activated fIX5. These data indicated that the intrinsic and 
extrinsic pathways were linked rather than separated from each other. The functionality 
of the extrinsic and the intrinsic pathways can be tested by two simple and routine 
laboratory coagulation tests, i.e., the prothrombin time (PT) and the activated partial 
thromboplastin (aPTT) assays, respectively (the tests will be further discussed under 
section 1.3). The terminology “intrinsic” and “extrinsic” pathways are convenient to use 
when discussing laboratory assays and which coagulation factors they measure. 
However, the coagulation cascade model does not always correspond well with clinical 
observations, e.g., why cannot the activation of fX by the extrinsic pathway compensate 
for a lack of fVIII or fIX in hemophiliacs?
Today it is widely accepted that the intrinsic and the extrinsic pathways are two 
overlapping phases (Figure 2) that can be recognized in the kinetics of thrombin 
generation, the so-called initiation and propagation phases.
1.1.2. Initiation and propagation of coagulation  
The clotting cascade can be triggered either via the extrinsic or TF pathway or the 
contact pathway (Figure 2 and Figure 3). The contact pathway of coagulation is 
initiated by the activation of fXII bound to an anionic surface in a reaction involving 
high molecular weight kininogen and plasma kallikrein. Recent studies have reported 
that inorganic polyphosphate (polyP), mostly released from platelets, binds to and 
activates fXII and can thereby directly trigger the contact pathway6. Initiation of 
coagulation by the contact pathway is not essential for hemostasis as people lacking 
fXII have no bleeding tendency7, initiation by the TF pathway is, on the other hand,
required for proper hemostasis8.
TF is a transmembrane protein primarily expressed in extravascular tissues and
coagulation is normally initiated when TF exposed to circulating blood binds to fVIIa.
The fVIIa/TF (extrinsic tenase) complex then converts zymogens fIX and fX to their 
active enzymatic forms. FXa provides rapid feedback activation of fVII bound to TF,
and converts small amounts of prothrombin (fII) to thrombin (fIIa). The small amounts 
of thrombin produced activates platelets9, and activates tiny amounts of plasma  
cofactors V and VIII to active cofactors fVa and fVIIIa10, and begins to cleave 
fibrinogen to fibrin.
15
Figure 2. Illustration of the “modern” coagulation system with its overlapping phases.
Thrombin (FIIa) is highlighted in red. Arrows indicate activation. Whole circles: 
proenzyms. Circles with a nick: activated coagulation factors. F ࡳ factor; a ࡳ activated; 
HK ࡳ high-molecular-mass kininogen; Plt ࡳ platelets; PL ࡳ phospholipids. Reprinted from 
Bishop and Lawson11, with permission.
Thrombin generation also leads to activation of fXIII, which is responsible for covalent 
cross-linking of fibrin12. These initial catalytic events provide the components needed
for the formation of the intrinsic tenase complex comprising cofactor VIIIa and fIXa,
and the prothrombinase complex comprising cofactor Va and fXa (Figure 3).
Vigorous thrombin generation occurs during the propagation phase when fIXa generated 
by the fVIIa/TF complex combines with cofactor VIIIa on the activated platelet surface 
to form the intrinsic tenase complex, which becomes the major activator of fX. The 
assembly of fX, fIXa, cofactor VIIIa and Ca2+ on phospholipid membranes enhance the 
activation of fX several orders of magnitude13;14. Consequently, the fXa generated by the 
Extrinsic tenase
Intrinsic tenase
Prothrombinase complex
16
intrinsic tenase complex supersedes the activation of fX by fVIIa/TF. The 
prothrombinase complex is formed by the assembly of activated fX and cofactor Va and 
Ca2+ on activated platelet membranes, and this complex accelerates the conversion of 
prothrombin to thrombin several hundred thousand times15. The tight assemblies of 
coagulation factors, cofactors and Ca2+ on phospholipid membranes make very efficient
catalytic complexes, resulting in a boost of thrombin formation.
Figure 3. The primary event that initiates coagulation (a) and propagation of thrombin 
generation (b) via assembly of the tenase and the prothrombinase complexes. Thrombin 
(FIIa) is highlighted in red. Arrows indicate activation. Whole circles: proenzymes. 
Circles with a nick: activated coagulation factors. F-factor; a-activated; From Bishop 
and Lawson11, with permission.
The major bolus of thrombin (>95%) is produced during the propagation phase after 
formation of the fibrin clot. Increased thrombin formation is necessary for the activation 
of thrombin activatable fibrinolysis inhibitor (TAFI), which is an inhibitor of 
fibrinolysis16. Fibrinolysis will be further discussed below. The major bolus of thrombin 
formation occurs within the fibrin mesh and it is believed that this last “bulk” of 
thrombin and the activation of TAFI are important to protect the clot from premature 
lysis17.
In the absence of cofactor VIII or fIX, the intrinsic tenase complex cannot be assembled, 
and no amplification of fX activation occurs. This is the principal defect observed in 
hemophiliacs. The blood of individuals with either severe hemophilia A or hemophilia B 
has no ability to generate the intrinsic tenase complex and hence is unable to support the 
propagation phase of coagulation18.
Intrinsic tenase 
complex
Prothrombinase 
complex
Extrinsic tenase 
complex
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1.1.3. Fibrinolysis 
A delicate balance between fibrin formation and fibrin dissolution is required to 
maintain adequate hemostasis and to prevent thrombus formation. Excess fibrin is 
removed by the fibrinolytic system. Plasminogen is the inactive precursor of the enzyme 
plasmin, which is the primary catalyst of fibrin degradation. Plasminogen is activated by 
tissue-plasminogen activator (t-PA) in the presence of fibrin19 or by factors of the 
contact pathway20. The proteins involved in fibrinolysis are recruited to the site of injury 
simultaneously with initiation of fibrin formation, i.e., the fibrin clot serves as a 
substrate and a surface for activation and localization of fibrinolytic proteins. The 
natural inhibitors of the fibrinolytic system are; TAFI, plasminogen activator inhibitor
type 1 (PAI-1) and type 2 (PAI-2), and Į2-antiplasmin. The net result of ongoing 
coagulation and fibrinolysis is the formation of fibrin degradation products, such as D-
dimer, which is specific for fibrin degradation. Overall reduced fibrinolysis is associated 
with increased risk for VT21.
1.1.4. Anticoagulant pathways 
Regulation of coagulation is exerted at each level of the coagulation pathway, either by 
enzyme inhibition or by modulating the activity of the cofactors. TF pathway inhibitor 
(TFPI), a glycoprotein mainly produced by vascular endothelium, and which exists in 
different forms in circulating blood, inhibits the fVIIa/TF catalytic complex in a fXa 
dependent manner. TFPI forms a complex with fXa and the TFPI/fXa complex then 
binds with high affinity to the fVIIa/TF complex, resulting in a fully inhibited 
quaternary TFPI/fXa/fVIIa/TF complex22.
Antithrombin (AT) binds to and irreversibly neutralizes the coagulation enzymes
generated during activation of coagulation. The activity of AT is greatly enhanced by 
glycosaminoglycans that are present on the surface of endothelial cells. The effect on 
AT is the molecular basis for the use of heparin as a therapeutic anticoagulant23.
Protein C (PC) is a vitamin K-dependent zymogen, and is the key component of the PC 
anticoagulant pathway. Thrombin bound to the membrane protein thrombomodulin on
intact endothelial cells activates PC. Protein S (PS) is a vitamin K-dependent cofactor 
protein that enhances the anticoagulant activity of activated PC (aPC). The accelerated 
activation of prothrombin (prothrombinase complex) and fX (tenase complex) are 
dependent on cofactors Va and VIIIa, respectively, and the activity of these two 
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cofactors is tightly regulated by the PC anticoagulant pathway. APC and PS form a 
membrane bound complex, which cleaves cofactors Va and VIIIa, even when they are 
assembled in the prothrombinase or tenase complexes. APC also cleaves intact cofactor 
V, resulting in anticoagulant cofactor V that functions in synergy with PS as cofactors 
for aPC in the degradation of cofactor VIIIa24. Recently, it has been shown that PS also 
has cofactor activity for TFPI and enhances the interaction between TFPI and fXa and 
thereby accelerates the feedback inhibition of fVIIa/TF by TFPI25. The PC and the TFPI 
pathways act in concert in down-regulating coagulation26.
1.2. Reduced sensitivity to activated protein C 
Functional defects of the PC pathway are quite common27 and can be detected in vitro
by aPTT or thrombin generation based assays (section 1.3) which probe the 
anticoagulant response of plasma to the addition of aPC. A poor anticoagulant response 
of plasma to exogenous aPC is known as aPC resistance28. The majority of people with 
an inherited cause of aPC resistance carry the F5 rs6025 polymorphism29. Because of a 
single nucleotide change in the fV gene, arginin is replaced by glutamin at the main aPC 
cleavage site in cofactor V and cofactor Va. Consequently, F5 rs6025 interferes with 
inactivation of both cofactor Va and cofactor VIIIa27, resulting in an aPC resistant 
phenotype and increased risk of VT30.
Given the complexity of the PC pathway, there are various possibilities of aPC 
resistance. Particularly, quantitative and qualitative alterations of the substrates and 
cofactors of aPC, as well as of the components of the tenase and the prothrombinase 
complexes, may influence the plasma response to aPC by affecting the rates of cofactor 
Va and/or cofactor VIIIa inactivation. Because the aPTT-based and the thrombin 
generation-based assays rely on different coagulation triggers and end-points, the assays
probe different coagulation reactions and are sensitive to different plasma factors. The 
effect of cofactor VIII levels is specific for aPC resistance in the aPTT-based assay, 
whereas low levels of PS and/or TFPI are major determinants of aPC resistance in TF-
triggered thrombin generation-based assays31.
Several acquired risk factors for VT such as pregnancy32, use of oral contraceptives33,
hormone replacement therapy34 and canser35 are associated with reduced sensitivity to 
aPC. During pregnancy36, and use of oral contraceptives37, the levels of PS and/or TFPI 
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decrease and since these proteins are major determinants of the thrombin generation-
based assay but not the aPTT-based assay, hormone-induced aPC-resistance is best 
detected by the thrombin generation-based assay38.
Of notice, from here and throughout the thesis, cofactors V and VIII are referred to as fV 
and fVIII.
1.3. Coagulation assays 
1.3.1. Activated partial thromboplastin time 
APTT measures the activity of the intrinsic and common pathways of coagulation. The 
term “partial” means there is phospholipids present but no TF. An activator, such as 
kaolin, silica, or ellagic acid, is added, and clotting is initiated when calcium is added to 
the solution. The aPTT is the time taken from the addition of calcium to the formation of 
a fibrin clot. Our laboratory uses an automated method for measuring aPTT and clot 
formation is considered to have occurred when the optical density of the mixture has 
reached a certain threshold. This threshold varies between laboratories. 
1.3.2. Thrombin generation assay 
While the end point of aPTT is the formation of a fibrin clot, which occurs when less 
than 5% of the total amount of thrombin is generated, the thrombin generation assay 
measures thrombin generation as a function of time, yielding a thrombin generation
curve (thrombogram), which reflects all phases of coagulation. There are several 
methods to measure thrombin generation. We used the calibrated automated 
thrombography (CAT) assay39, which is performed in a microtitre plate. Thrombin 
activity in plasma is continuously registered by fluorescence readings which are 
automatically converted into thrombograms by dedicated software. Figure 4 shows a 
typical thrombogram and the many parameters that can be derived from the thrombin 
generation curve. 
The lag time is arbitrarily defined as the moment when 10 nM thrombin is formed and 
shows a good correlation to plasma clotting time measured by aPTT. The endogenous 
thrombin potential (ETP) is the area under the curve and represents the total amount of 
thrombin generated during the test. Of the parameters derived from the thrombogram, 
ETP is considered the most predictive parameter of thrombosis39-41.
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Figure 4. Thrombogram by the Calibrated Automated Thrombography assay. From The 
Calibrated Automated Thrombogram®, www.thrombinoscope.com
The assay outcome is dependent on the experimental conditions used (so-called assay 
determinants) as they influence which pro-and anticoagulant pathways contribute to the 
shape of the thrombogram. The TF concentration used to trigger coagulation and 
addition of aPC to the assay are such determinants. The thrombin generation assays are 
also influenced by biological variables such as age42, pregnancy43 and use of combined 
oral contraceptives44, all of which affect the levels of certain coagulation factors and 
inhibitors. Furthermore, the thrombogram may be hampered by preanalytical variables 
such as blood collection and plasma preparation45.
Normalization 
The term “normalization” has a range of meanings. When we use the term “normalized” 
for a laboratory result, it refers to a simple calculation where the result from test plasma 
has been divided by the result obtained with reference plasma (Figure 5). Normalization 
of laboratory test results has become a valid method to increase reproducibility and 
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improve inter-center variability of results46-48. We used pooled normal plasma (PNP) 
(described in section 3.3.) as “normal plasma”. 
A.        
aPC sensitivity ratio = 
B.  
Normalized aPC sensitivity ratio = 
Figure 5. A. Activated protein C (aPC) sensitivity ratio. B. Normalized aPC sensitivity 
UDWLR(73ࡳ endogenous thrombin potential.
1.4. Antiphospholipid antibodies 
Antiphospholipid antibodies (APAs) comprise a heterogeneous group of antibodies and 
the major target antigen is beta-2-glycoprotein 1 (ȕ2GP1)49;50. As illustrated by Figure 6,
ȕ2GP1 circulates in plasma in a circular conformation. When ȕ2GP1 binds to a 
phospholipid surface, ȕ2GP1 undergoes a conformational change and uncovers epitopes
which are recognized by a substantial proportion of anti-ȕ2GP1 antibodies. These 
antibodies are both cardiolipin-positive and have lupus anticoagulant activity51;52.
Binding of the epitope by the antibody fixes ȕ2GP1 in the “new” unfolded 
conformation. The antibody- ȕ2GP1 complex can then interact with several surface 
receptors. APAs are thought to induce thrombosis by interfering with pro-coagulant, 
anticoagulant and fibrinolytic systems53.
Diagnosing the antiphospholipid syndrome (APS) requires at least one positive 
laboratory test for APAs (lupus anticoagulant (LA), anticardiolipin antibodies (aCL) or 
ȕ*3-1 antibodies) performed on two occasions at least 12 weeks apart, and the 
presence of thrombosis and/or pregnancy morbidity i.e. unexplained death(s) of a fetus 
at or beyond the 10th week of gestation, premature birth(s) before the 34th week of 
gestation  because of eclampsia or severe preeclampsia, or recurrent spontaneous 
abortions before the 10th week of gestation54.
ETP with aPC
ETP without aPC
ETP with aPC / ETP without aPC Test plasma
ETP with aPC / ETP without aPC Normal plasma
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Figure 6. Sequence of events leading to cellular activation by beta-2-glycoprotein 1 
(ȕ2GP1) antibody complexes. From de Groot and Urbanus55, with permission.
1.4.1. Detection of antiphospholipid antibodies  
APAs are detected by functional assays and by enzyme-linked immunosorbent assays 
(ELISAs).  
Functional assays for lupus anticoagulants 
LAs are a heterogeneous group of antibodies which prolong phospholipid-dependent 
coagulation assays, among others; aPTT and the Russell’s viper venom time (RVVT). 
The Russell’s viper venom isolated from the snake Daboia russelii contains a potent 
activator of fX, which in the presence of phospholipids, prothrombin and calcium 
activates fibrinogen to fibrin. To optimize the sensitivity to LAs, Russell’s viper venom 
is diluted to give a certain clotting time in normal plasma. 
Detection of LAs includes three steps: screening, mixing and confirmation tests. The 
screening tests are most often LAs sensitive aPTT (low phospholipid concentration) or 
dilute RVVT (dRVVT) tests. The preparation of platelet-poor plasma is important as 
platelets provide phospholipids and residual platelets in plasma can cause false negative 
tests.
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The second step involves mixing test sample with normal plasma, usually 1:1, before the 
test is repeated. This step is to differentiate between inhibitors of coagulation and 
coagulation factor deficiencies as cause for prolonged clotting times. The final 
confirmatory step demonstrates the phospholipid dependency of the antibody as the 
clotting time is normalized in the presence of excess phospholipids. The confirmation 
test must be performed with the same assay principle that was employed in the positive 
screening test56.  In our laboratory, the principles of these three assays are integrated into 
one assay and the results are normalized against results obtained from PNP run in 
parallel.  
Enzyme-linked immunosorbant assay (ELISA) 
ACL antibody ELISA detects antibodies directed against ȕ2GP1 dependent aCL, 
whereas ȕ2GP1 ELISAs measure only antibodies against ȕ2GP1. The antibody isotypes 
of interest for the diagnosis of APS are IgG and IgM present at a certain titre.   
The epitopes uncovered by the ȕ2GP1conformational change are recognized by anti-
ȕ2GP1 antibodies which are both aCL-positive and have LA activity51;52This means, that 
the same antibody might be recognized by the three different assay systems (the 
coagulation assays detecting LAs and the ELISA assays detecting aCL and ȕ2GP1).
Antibodies recognized by all three assay systems have the strongest association with 
VT57.
1.5. Venous thrombosis 
The overall incidence rate of a first event VT in the adult population is approximately 
1.4 per 1000 person years58. The incidence of VT is strongly age dependent, the 
incidence rate being three times higher for persons aged 70 years or above than those 
aged 45-69 years, which again is three times higher the rates in persons aged 20-44 
years58. The most common presentations of VT are DVT of the lower limbs and PE.
Sometimes VT may occur in other deep veins, such as in the upper limbs, in the 
mesenteric veins including the portal vein, in the liver vein, and in cerebral sinuses. Two 
important sequalae may arise after DVT or PE; post thrombotic syndrome (PTS) and 
chronic thromboembolic pulmonary hypertension (CTPH). PTS occurs in 20-50% of VT 
patients and can result in chronic calf swelling which may lead to skin ulcer, sustained 
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itching or pain in the affected leg59. CTPH is defined as a mean artery pressure above 25
mm Hg that persists for >6 months after a diagnosis of PE. The disorder occurs in 2-4% 
of patients after acute PE and results in disabling dyspnea60.
In 1856 Dr. Virchow postulated that thrombosis was due to stasis of the blood, changes 
in the vessel wall, or changes in the composition of the blood, now commonly known as 
the Virchow’s triade61. Genetic risk factors for VT lead to hypercoagulability (changes 
in the composition of the blood), whereas the acquired causes are either associated with 
decreased flow (stasis) or related to hypercoagulability (Table 1). Increased risk of VT 
due to hypercoagulability is commonly referred to as thrombophilia. Thrombophilia are 
detectable in more than 50% of patients with a first unprovoked VT62. Contrary to 
arterial thrombosis, where structural changes of the vessel wall play a key role, much 
less is known about the role of the vessel wall in non-traumatic VT. Normally, 
endothelium has anticoagulant properties, whereas in response to variation in blood flow 
and/or oxygenation the endothelium can convert to a pro-coagulant phenotype63.
1.5.1 Inherited and acquired risk factors for venous thrombosis 
VT is a multicausal disease, i.e., several risk factors need to be present simultaneously to 
cause thrombosis. As illustrated by Figure 7, an individual’s thrombotic potential may 
be described as being dynamic age-dependent with inherited and acquired risk factors 
increasing the risk for VT in an additive or synergistic fashions64.
The strongest risk factor for VT is being affected by a previous VT. After 5 years of 
follow-up a recurrence rate of approximately 25% have been reported65. Age is another 
strong risk factor for VT, illustrated by Figure 7. The risk of VT increases approximately 
50 times from 20 to 70 years of age. Other acquired risk factors for VT are listed in 
Table 1.
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Figure 7. Each solid line (red, yellow, green) represents an individual’s thrombotic 
potential. The stippled boxes represent situations where the persons are disposed to 
increased risk of venous thrombosis, e.g. pregnancy, surgery or use of combined oral 
contraceptives. Modified after Rosendaal FR64.
Genetic thrombophilia (Table 1) is commonly divided into loss-of-function and gain-of-
function mutations. The loss-of-function mutations are limited to genes that encode 
proteins with anticoagulant properties, whereas gain-of-function mutations encode pro-
coagulant proteins.  
In the general population the prevalence of deficiencies of the natural anticoagulants are 
rare, probable due to loss of mutant alleles from the gene pool through critically ill 
homozygous individuals66. AT deficiency is found in approximately 1:2000-1:5000, and 
the prevalence of PC deficiency is between 1:200-1:50067;68. The prevalence of PS 
deficiency in the general population is uncertain69. Inherited deficiencies of these natural 
anticoagulants represent strong risk factors for VT with relative risks ranging from 5-50 
according to the defect and the population investigated69-73.
F5 rs6025 polymorphism, phenotypically expressed as reduced sensitivity to aPC, is the 
most common thrombophilia among Caucasians. In Europe the frequency of F5 rs6025
polymorphism is between 2-15% in the general population, whereas it is rare in the rest 
of the world74. In heterozygous carriers, the risk of VT is increased 3 to 8-fold, and in 
homozygous 50 to 80-fold75;76. F5 rs6025 is a weaker risk factor of VT than deficiencies 
of the natural anticoagulants, but being far more common, it has greater impact as a risk 
factor in the general population.  
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Another common genetic polymorphism in Caucasians is the F2 rs1799963
polymorphism (commonly known as the prothrombin gene G20210A mutation), 
resulting in elevated plasma levels of prothrombin. The prevalence of carriers varies 
between 1-4% in the general population with a higher prevalence in southern than in 
northern Europe77. Carrying this polymorphism increases the risk of VT about a 3-fold78.
Because of the rarity of homozygous carriers of F2 rs1799963 information is uncertain 
regarding homozygous carriers and risk of VT77;79.
As both the F5 rs6025 and the F2 rs1799963 polymorphisms are relatively common in 
the Caucasian population, their combined presentation is not rare. Family members, who 
are heterozygous for both polymorphisms, have six times increased risk of VT as 
compared with non-affected family members80.
There is evidence that the levels of coagulation factors are regulated by genetic factors81,
and if so, familial thrombophilia may not be restricted to deficiencies in the natural 
anticoagulants or the F5 rs6025 or F2 rs1799963 polymorphisms. Interestingly, having a 
positive family history of VT (i.e., at least one 1st degree relative with VT) 
independently of inherited thrombophilia increases the risk of VT more than 2-fold. 
Moreover, individuals with VT more often have a positive family history than 
individuals without VT, even when known risk factors are similar. This finding suggests
that other, but yet unknown genetic factor(s), may be involved82.
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1.5.2. Differential risk factors for deep vein thrombosis and pulmonary embolism 
There has been a consistent reporting that DVT patients more often are carriers of F5 
rs6025 polymorphism as compared with PE patients. This phenomenon is often referred 
to as the factor V Leiden paradox101-105. In a recent review by van Langvelde et al on
differential risk factors for DVT and PE, obesity, use of combined oral contraceptives,
and pregnancy and puerperium were found to increase the risk for DVT106. The authors 
concluded that the differential effects of these risk factors could be explained through 
reduced sensitivity to aPC in these conditions. Pulmonary inflammatory diseases and 
sickle cell disease increased the risk of PE. Conflicting results have been reported 
regarding the F2 rs1799963 polymorphism and different risk for DVT or PE. Van 
Langevelde et al found no difference in risk for DVT and PE in carriers and non-carriers 
of the F2 rs1799963 polymorphism. These observations support the comprehension that 
DVT and PE may be partly different diseases. Investigations of differential hemostatic 
risk factors for DVT and PE, besides the F5 rs6025 and F2 rs1799963 polymorphisms, 
have not previously been published.  
1.6. Physiological changes in coagulation during pregnancy 
Normal pregnancy is associated with increased concentrations of most clotting factors, 
decreased or unchanged concentrations of natural anticoagulants and reduced fibrinolysis
(Table 2). These changes are interpreted as mainly being due to increased estrogen 
levels107. After delivery, the changes in blood coagulation and fibrinolysis reach levels 
seen outside pregnancy within 3-6 weeks postpartum108.
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Table 2. Physiological changes of coagulation factors, natural anticoagulants and 
parameters of fibrinolysis during normal pregnancy. ×– Increased levels; Ø– decreased 
levels; Ù– unchanged levels.
Coagulation
factors
Natural 
anticoagulants
Fibrinolytic
parameters 
fibrinogen107 × AT109 Ù tPA110 Ø
fII109 × PC109 Ù uPA111 ×
fV107 × PS109 Ø PAI-1112 ×
fVII107 × TFPI36 Ø PAI-2112 ×
fVIII107 × aPC sensitivity109 Ø D-dimer113 ×
fIX107 ×
fXI114 Ø
fXII109 ×
fXIII109 ×
1.6. 1. Venous thrombosis in pregnancy and postpartum 
Virchow’s triade of underlying factors in VT are all present in pregnancy. During vaginal 
or abdominal delivery endothelial damage to pelvic vessels can take place. 
Approximately 85% of pregnancy-related DVTs affect the left leg and this lateralization 
might be due to the compression of the left iliac vein by the right iliac artery which cross 
the vein on the left side only (May-Thurner syndrome)115;116. The hemostatic changes that 
occur in normal pregnancy (Table 2) steer hemostasis in a “coagulable” direction. This 
protects pregnant women from severe bleeding during delivery but at the same time leads 
to a hypercoagulable phenotype that disposes for VT117. The incidence of pregnancy 
related VT is approximately 1 per 1000 pregnancies118, which is 5-10 times higher than 
would be expected for women in that age group119, and fatal PE accounts for 1.1 deaths 
per 100000 deliveries120. In a previous study by our group, the incidence of fatal VT was 
found to be 0.48/100000 deliveries118. Although rare, VT is one of the main causes of 
maternal mortality in developed countries117;121-123.
Pregnancy-related VT is equally distributed during pregnancy and within 3 months after 
delivery. The highest risk is found in the third trimester and the first 3 weeks postpartum 
(Figure 8). Furthermore, DVT is the most common presentation during pregnancy 
whereas PE is most common diagnosed after delivery118.
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Figure 8. Distribution of VT in pregnancy and postpartum. 97(ࡳ venous thrombo-
embolism. From Jacobsen et al118, with permission.
1.6.2. Risk factors for pregnancy related venous thrombosis 
Our group has previously reported on clinical risk factors for VT during pregnancy or 
postpartum118. Immobilization during pregnancy and obesity were important risk factor 
for both antenatal- and postnatal VT. Women who smoked cigarettes had increased risk 
for both antenatal and postnatal VT. Furthermore, assisted reproductive therapy and small 
maternal weight gain during pregnancy were risk factors for antenatal VT, whereas 
preeclampsia, intrauterine growth restriction and complications such as surgery, heavy 
bleeding and infection, associated with labor and Cesarean section were risk factors for 
postnatal VT. 
Whether or not alterations in hemostatic factors associated with VT in the general 
population affect the risk of pregnancy-related VT is incompletely described. Carrying 
the F5 rs6025 or the F2 rs1799963 polymorphisms increases the risk for pregnancy-
related VT approximately 5- and 9-fold, respectively124-126. Reviewing 9 studies, of which 
4 studies investigated deficiencies of the natural anticoagulants and risk of VT during 
pregnancy or postpartum, Robertson et al concluded that deficiencies of AT, PC and PS 
increased the risk of pregnancy-related VT approximately 3-5 fold as compared with non-
carriers of the deficiencies127. A possible association between the levels of fibrinogen, 
fVIII, fIX, and D-dimer, and the risk of pregnancy-related VT has not previously been 
described. 
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2. Aims 
We hypothesized that abnormal levels of hemostatic parameters known to increase the 
risk of VT in the general population also increase the risk of a first time VT during 
pregnancy or the postpartum and furthermore, that some of these hemostatic parameters
are associated with differential risk for pregnancy-related DVT and PE. Given our 
hypotheses, the aims for the present thesis are:
x To investigate whether high or low levels of selected hemostatic parameters
increase the risk of VT during pregnancy or the postpartum (Paper I).
x To study differential risk for DVT and PE for hemostatic parameters associated 
with pregnancy-related VT (Paper I).
x To investigate whether reduced sensitivity to aPC in both non-carriers and carriers 
of the F5 rs6025 polymorphism is associated with increased risk of VT during
pregnancy or the postpartum (Paper II).
x To investigate whether APAs either alone or in combination, and in relation to the 
F5 rs6025 and the F2 rs1799963 polymorphisms, increase the risk of pregnancy-
related VT (Paper III).
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3. Materials and Methods  
3.1. The original VIP study-population 
The study-populations defined in the registry-based and the hospital-based studies 
published by Jacobsen et al118;128 are briefly described below. For the studies included in 
this thesis, eligible participants from the hospital-based study met for further 
investigations as described under section 3.2.
3.1.1. Case ascertainment 
From January 1st 1990 to December 31st 2003, 1231 women with a first time VT in 
pregnancy or 3 months postpartum (cases) were identified in 18 hospitals localized in 11 
of 19 Norwegian counties118. The cases were identified by search for selected 
international classification of diseases (ICD) codes in the Norwegian Patient Register 
using the ICD versions 8, 9 and 10 codes (Table 3).
In the hospital-based VIP study-population128, eligible hospital records from the cases 
identified in the Norwegian Patient Register were reviewed and each case was validated 
for VT. The hospital-based study finally comprised 559 cases (Figure 9).
Table 3. International classification of diseases (ICD) codes for cases selection
ICD 8
433                    Cerebral vein thrombosis
450                    Pulmonary embolism
452                    Portal vein thrombosis
453                    Venous thrombosis
671                    Venous thrombosis in puerperium
673                    Pulmonary embolism during pregnancy and puerperium
ICD 9
325           Phlebitis and thrombophlebitis of intracranial venous sinuses
415.1                 Pulmonary embolism
451                    Venous thromboembolism
452                    Portal vein thrombosis
453                    Other vein thrombosis
671.3 ,4 ,5 ,9     Deep phlebothrombosis, antepartum, postpartum and other
                          thrombosis during pregnancy
673.2 , 3            Obstetric blood clot embolism, puerperal pulmonary
ICD 10
G 08                  Phlebitis and thrombophlebitis of intracranial venous sinouses
I 26                    Pulmonary embolism
I 80                   Venous thromboembolism
I 82                   Other venous thrombosis
O 22.3,5,8,9     Venous complications in pregnancy
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Figure 9. Flow-chart describing the selection of cases from the registry-based to the 
hospital-based study-population.
3.1.2. Ascertainment of the diagnosis of VT 
Reviewing the hospital records, the diagnosis of DVT was accepted when it was 
confirmed by compression or color ultrasonography or by venography. The diagnosis of 
PE was accepted when objectively verified by perfusion lung scanning, computed 
tomography, magnetic resonance imaging or by angiography. Patients with suspected but 
not objectively verified VT were excluded. 
3.1.3. Control selection 
All pregnancies within the same area (18 hospitals) and period of time (1990-2003) were 
possible controls, in total 616236 pregnancies. The controls had no history of VT and 
were identified by the Medical Birth Registry (MBR) of Norway118.
In the hospital-based study128 all controls were selected from Oslo university hospital, 
Ullevål (formerly Ullevål University Hospital). The selection of controls was done by a 
software program run by the MBR of Norway. First all cases from the participating 
hospitals were identified and from this data file a list of cases was prepared by the 
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11-digit personal identification number, which is unique for all Norwegian citizens, and 
date of delivery. By date of delivery, MBR of Norway selected 4 women who gave birth 
at the same time as a case as possible controls, regardless of hospital where the case 
delivered. The first two controls were selected, and then the 3rd and 4th control, in that 
order, if records were not available. 
3.2. The VIP study-population used in the studies included in this thesis  
As we wanted to study hemostatic biomarkers and the risk for pregnancy-related VT, we 
invited eligible cases and controls from the hospital-based VIP study-population to 
answer a questionnaire and donate blood during the year 2006. 
3.2.1. Case ascertainment 
531 eligible cases were invited for blood sampling and answering a questionnaire at the 
hospital the VT was diagnosed. After two reminders, 316 cases agreed to participate in 
the study. Blood sampling failed for one case and the questionnaire revealed that two 
cases had been treated for previous VT. The final study population comprised 313 cases 
(Figure 10).  
3.2.2. Control selection 
1092 eligible controls from the hospital-based study population were invited to donate 
blood sample and answering a questionnaire at Oslo University Hospital at Ullevål
(Figure 10). After two reminders 356 controls agreed to meet at Oslo University Hospital 
at Ullevål. As 3 controls did not complete the questionnaire the final control population 
comprised 353 controls (Figure 10).
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Figure 10. Flow-chart showing the final selection of cases and controls participating in 
the studies presented in the present dissertation.
3.3. Blood sampling and analysis 
For the controls, blood samples were drawn at Oslo university hospital at Ullevål. The 
cases met at the hospital they had had their index VT and two investigators from the VIP 
study met at the respective hospitals and draw and prepared blood samples from the cases
as described below.
Venous blood samples were drawn from fasting women at a single time point during 
2006, 3-16 years (median 8 years) after index pregnancy, and citrated blood was kept at 
room temperature and centrifuged at 2000g for 15 minutes within 1 hour to prepare 
platelet poor plasma. Plasma aliquots were stored at -70 °C until assayed. All analyzes 
were performed by skilled technical staff with long experience in our research laboratory. 
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At time of blood sampling, self-reported morbidity was low, and none of the women had 
hematologic disease, active cancer, thyroid disorder, or inflammatory bowel disease. 
Anti-allergy drugs were used in approximately 10% of both cases and controls. Less than 
5% of the cases and the controls used other daily medications, such as antihypertensives, 
insulin, and antidepressants. 
Citrated plasma was used to measure levels of coagulation factors and inhibitors, markers 
of activated coagulation and fibrinolysis and APAs. DNA was analyzed from whole 
blood collected in containers with EDTA. Details on the specific analysis are given in 
Papers I, II and III. All analyses were performed examiner blind, and the samples were 
run in batch using a balanced set-up with equal number of cases and controls in each run. 
The functionality of the PC system was analyzed by testing the effect of aPC on the ETP
as determined by the CAT assay (Figure 11). Coagulation was triggered by recalcification 
of citrated plasma in the presence of 5 pM recombinant human TF. We used 6.5 nM aPC 
which gave a residual thrombin generation activity of 15-16% in PNP. The aPC 
sensitivity ratio (aPC-sr) was defined as the ETP in presence of aPC divided by ETP 
without aPC (Figure 5 section 1.3.2.). In order to increase reproducibility, all test results 
were expressed as normalized aPC-sr (n-aPC-sr). High levels of n-aPC-sr reflect an aPC 
resistant phenotype.
Figure 11. Functionality of the protein C system with and without exogenous aPC.
ETP ࡳ endogenous thrombin potential; aPC ࡳ activated protein C.
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The assays were performed at the Haematological Research Laboratory at the Department 
of Haematology, Oslo University Hospital. Intra-assay coefficients of variation (CV) 
were: factor VIII 2.7%, factor IX 5.3%, AT 2.9%, PC 1.8%, free PS antigen 4.4%, free 
TFPI 4.1%, and D-dimer 7.7%, all consistent with good internal validity.
PNP was prepared from 21 healthy blood donors. Citrated blood was centrifuged at 2000 
g for 15 min. within 1 hour, pooled and stored at -700C. Residual platelet count in 
individual plasmas was <5Â109 /L before pooling. The men and women from whom the 
plasmas were prepared did not have thrombophilia. None of the women used oral 
contraceptives, hormone replacement therapy, and none were pregnant. We used the same 
PNP in Papers I-III.
3.4. Statistics 
The distribution of continuous variables was evaluated by inspecting their histograms.
For approximately normally distributed variables, parametric statistics were used and data 
were reported as mean and standard deviation (SD), whereas non-parametric statistics 
were applied for skewed variables and data were reported as medians, quartiles and 
percentiles. When exploring associations between two dichotomized variables, unadjusted 
odds ratios (OR)s were calculated using 2x2 cross-tables. Adjusted ORs were calculated 
using multiple logistic regressions. ORs with 95% CI and a significance level of 5% were 
used in all three papers.
In Papers I and II women being pregnant, using oral contraceptives or anticoagulation at 
time of blood sampling were excluded when we analyzed the phenotypic hemostatic 
variables.
Cut-offs for high or low levels of the hemostatic variables and APAs were defined in the 
control group.
In Paper I the ORs for DVT and for PE as compared with controls were calculated for 
hemostatic and genetic variables by using logistic regression. High sensitivity (hs) C-
reactive protein (CRP) values were logarithmically transformed for calculations of mean 
hsCRP levels.
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In Paper II the association between n-aPC-sr and VT was analyzed in two subpopulations: 
1) in non-carriers of F5 rs6025 and 2) in carriers of F5 rs6025. The n-aPC-sr quartile and 
percentile limits were defined in the controls in the two subpopulations, respectively. 
Unadjusted and adjusted ORs were studied by using logistic regression models.
Spearman’s correlation coefficient was used when associations between two continuous 
variables were analysed and a two-sided Mann-Whitney test was used when comparing 
n-aPC-sr in two groups. When comparing n-aPC-sr in more than two independent groups, 
the Kruskal-Wallis test was used.
In Paper III the data were analyzed using chi-square test or Fisher’s Exact Test.
The statistical analysis was performed by using the statistical software program SPSS, 
versions 16, 18 and 19.
3.4. Approvals  
The research protocol was approved by the Regional Committee for Research Ethics in 
Health Region East and the Norwegian Ministry of Health and Social Affairs. The 
Norwegian Data Inspectorate approved the processing of data files with sensitive personal 
health information and merging of clinical data and register data. Informed consent was 
collected from the participants at the time of blood sampling. The study was registered at 
www.clinicaltrials.gov, unique identifier number NCT00856076, with acronym Venous 
Thromboembolism in Pregnancy (VIP) study.
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4. Summary of results 
4.1. Paper I 
Differential hemostatic risk factors for pregnancy-related deep vein thrombosis and 
pulmonary embolism - A population-based case-control study
In paper I we investigated whether high or low levels of hemostatic parameters known to 
be risk factors of VT in the general population were associated with VT during pregnancy 
or the postpartum, and whether these parameters showed differential risk for pregnancy-
related DVT and PE. We adjusted each hemostatic variable for high-sensitivity CRP (hs-
CRP), age and the time interval between index pregnancy and the time for blood 
sampling. FVIII, n-ETP and D-dimer levels above the 90th percentile were independent 
risk factors for pregnancy-related VT; aORs 1.9 (95% CI 1.2 ࡳ 3.1), 2.1 (95% CI 1.3 ࡳ 3.3) 
and 2.3 (95% CI 1.4 ࡳ 3.7), respectively. After adjusting for hsCRP, fIX above the 90th
percentile was no longer associated with VT. However, fIX above the 90th percentile was 
an independent risk factor for PE, aOR 2.4 (95% CI 1.1-5.0). Low levels of free PS
antigen (at or below 65% in controls) increased the risk for PE three times as compared 
with controls, aOR 3.1 (95% CI 1.3-7.2), whereas the risk for DVT was not increased. 
The risk for DVT was increased in both carriers and non-carriers of F5 rs6025 
polymorphism (commonly known as factor V Leiden). aOR for DVT as compared with 
controls for n-aPC-sr above the 75th percentile in non-carriers of F5 rs6025 polymorphism 
was 3.3 (95% CI 2.1-5.2). For women carrying F5 rs6025 polymorphism, OR for DVT as 
compared with controls was 7.7 (95% CI 4.7 ࡳ 12.7). Reduced sensitivity to aPC was not 
associated with increased risk for PE. 
In conclusions, high levels of fVIII, n-ETP and D-dimer were independent risk factors for
pregnancy-related VT. Reduced sensitivity to aPC increased the risk for DVT in absence 
of F5 rs6025 polymorphism and in carriers of F5 rs6025 polymorphism, whereas high 
levels of fIX and low levels of free PS antigen increased the risk of pregnancy-related PE.
42
4.2. Paper II 
Resistance to activated protein C is a risk factor for pregnancy related venous 
thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism
In the second paper we investigated the association between reduced sensitivity to aPC,
expressed as n-aPC-sr, and the risk of VT in pregnancy or the postpartum in non-carriers 
and carriers of the F5 rs6025 polymorphism (commonly known as factor V Leiden).
Women, who were pregnant or used oral contraceptives or anticoagulation therapy at time 
of blood sampling, were not included in the analyses. The association between n-aPC-sr 
and VT was analyzed in two subpopulations: 1) in non-carriers of F5 rs6025 
polymorphism and 2) in carriers of F5 rs6025 polymorphism. When we analyzed aPC 
resistance in women not carrying F5 rs6025 polymorphism, n-aPC-sr quartiles were 
defined in F5 rs6025 polymorphism negative controls. In F5 rs6025 polymorphism non-
carriers, the risk of VT was more than doubled in women with n-aPC-sr in the 4th quartile
as compared with women having n-aPC-sr in the 1st quartile; OR 2.3 (95% CI 1.4-3.9). 
Adjusting for age, free TFPI, free PS antigen and the time interval between index 
pregnancy and blood sampling had little influence on the association between VT and 
n-aPC-sr. 
To investigate whether an aPC resistant phenotype increased the risk of VT in carriers of 
F5 rs6025 polymorphism, we defined n-aPC-sr quartiles in F5 rs6025 polymorphism
positive controls. Including only F5 rs6025 polymorphism carriers in the analyses, the 
risk of VT was increased with higher n-aPC-sr, but not statistical significant. The OR for 
VT for n-aPC-sr above the 90th quartile as compared with n-aPC-sr at or below the 90st
quartile was 3.7 (95% CI 0.8-17.1).
In conclusions, aPC resistance in absence of F5 rs6025 polymorphism is a risk factor for 
pregnancy-related VT, and there is a relation between an aPC resistant phenotype and risk 
of VT in carriers of F5 rs6025 polymorphism.
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4.3. Paper III 
The association of antiphospholipid antibodies with pregnancy-related first time 
venous thrombosis - a population-based case-control study
In paper III we investigated the association between LAs, aCLs and anti-ß2GP1
antibodies and pregnancy-related VT. According to international consensus, the 99th
percentiles for the different APAs in the control group were used as cut-off values. There 
was no association between pregnancy-related VT and being positive for at least one 
APA. Nine cases and no controls had two or more positive tests for APA (=multi-
positive). Excluding women with IgM (aCL and anti-ß2GP 1) antibodies from the 
analyses, seven cases were still APA multi-positive. 6 cases were still multi-positive for 
APA after carriers of the factor V Leiden or the prothrombin polymorphisms were 
excluded from the analyses. Separate analyses for women with index pregnancy during 
1990 through 1996 and during 1997 through 2003 revealed no significant difference
between the numbers of women positive for any APA in the two time periods.
In conclusion, multi-positivity for APAs is strongly associated with pregnancy-related 
VT.
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5. General Discussion  
5.1. Methodological considerations, strengths and limitations 
5.1.1. Study design and study population 
Our study has a case-control design. This design was chosen because the incidence of 
pregnancy-related VT is low, and because we aimed at identifying risk factors for 
pregnancy-related VT.
The large number of cases included in this study and the population based design are 
strengths of the studies presented in this thesis. Furthermore, the diagnoses of VT were 
validated by reviewing hospital records, ensuring that all VTs were objectively diagnosed 
and they were the first lifetime VT. 
Control selection 
The selection of controls from a single hospital was done because of administrative 
matters and limited funding. Nevertheless, this selection is a potential weakness of the
study. Because the controls were selected from a more restricted geographic area than the 
cases, the controls do not fully represent the population from which the cases were 
selected (the source population). In case-control studies the controls are used to estimate 
the distribution of potential risk factors in the source population and the controls should 
therefor ideally be selected from the entire source population. To limit this weakness, the 
study was planned in such a way, that it is possible to describe the distributions of 
potential risk factors for VT within the different study populations. Columns B and C of 
Table 4 display the distribution of risk factors for pregnancy-related VT among the 
controls selected from one hospital (n=1229) and the controls selected from all 18 
hospitals (n=613232), respectively. Overall, the differences were nominally small, but the 
controls in population B were older, had lower parity and had more often Cesarean 
section than the controls in population C. As described earlier, the risk of VT increases 
progressively with increasing age, but age was not associated with pregnancy-related VT 
in our previous study on clinical risk factors128 and age did not affect our risk estimates 
when we adjusted for maternal age in the multivariate analyses. This may be explained by
the participants being too young to demonstrate an “age-effect” on the risk of VT. The 
hemostatic variables we studied were not associated with parity or Cesarean section. If 
the controls are selected in such a way that they become more similar to the cases, 
estimates for the variables might be biased towards null and thereby we might not detect a 
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difference for the variables between cases and control that actually exists (Type II errors).
If, on the other hand, the controls are selected in such a way that they become more 
different from the cases, risk estimates will be overestimated (Type I errors).
Table 4. Distribution of potential risk factors for pregnancy-related VT among the cases 
(Column A), among controls selected from Oslo University Hospital, Ullevål (Column B) 
and among controls selected from the source population (Column C).
Risk factor
Cases
A
N=559
Controls -
one hospital
B
N=1229
Controls –
all births
18 hospitals
C
N=613232
% % %
Age 
(years)
17-24 19.1 13.5 18.3
25-29 31.5 29.9 35.5
30-34 28.8 32.1 31.4
35-54 20.6 24.6 14.8
Parity 0 53.0 48.3 43.5
1 27.0 33.4 35.1
2 13.2 12.5 15.9
3+ 6.8 5.8 5.6
Conceived after ART 5.0 1.9 0.8
Multiple pregnancy (twins) 4.7 2.1 1.6
Preeclampsia 11.4 4.7 3.5
Diabetes 1 0.2 0.4 0.6
Gestational diabetes 1.3 1.1 0.5
Premature rupture of membranes 2.9 0.2 5.2
Placenta abruption 2.1 1.0 0.6
Vaginal  delivery 68.0 80.6 87.3
Planned Cesarean 8.9 9.2 4.8
Acute Cesarean 23.1 10.2 7.9
Vaginal delivery comprises vaginal, vacuum and forceps delivery. Immobilization is 
defined as strict bed rest one week or more prior to the diagnosis of VT or prior to 
delivery, in controls strict bed rest one week or more at any time during pregnancy. 
$57ޤDVVLVWHGUHSURGXFWLYHWKHUDS\%0,ޤERG\PDVVLQGH[.
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Drop-outs  
A common problem in epidemiological studies, and also a concern in the studies 
presented in this thesis are potential selection bias caused by drop-outs. Selection bias is a 
systematic error which appears when the association between the risk factor and the 
disease are different for those participating and those not participating in the study. We
provided information on clinical risk factors from medical files both for participants and
non-participants and have, in contrast to many other studies, presented the source 
population and the selection of cases and controls. All eligible women from the hospital-
based study were invited to participate in the study presented in this thesis, but a 
substantial number, approximately 40% of the cases and 70% of the controls declined. 
Table 5 shows the distribution of potential risk factors for pregnancy-related VT between 
eligible cases and controls participating and not participating. As showed by table 5,
participating controls were older than non-participating controls and older than 
participating cases. Except for age, potential clinical risk factors were fairly distributed 
between participating and non-participating women and the direction of the selection bias 
of clinical risk factors was mainly the same for the cases and controls participating and 
not participating (Table 5). Thus our study appears to suffer from some degree of 
selection bias, but we still consider our results to have good external validity. 
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Table 5. Distribution of possible risk factors for pregnancy-related VT among eligible 
cases and controls who agreed/did not agree to participate in the study.
Weight gain *less than the 10 percentile, **between the 10th and 90th percentile and ***
more than the 90th percentile; ART ࡳ assisted reproductive therapy; BMI ࡳ body mass index; 
,PPRELOL]DWLRQࡳ strict bed rest one week or more prior to the diagnosis of VT, in controls 
strict bed rest one week or more at any time during pregnancy.
Ethnicity  
The participants who donated blood samples were mainly Caucasian, 90.1% of the 
controls and 95.8% of the cases had parents who were both from north-western Europe. A 
larger portion of the controls than the cases had other ancestors than north-western 
Europeans, probably reflecting the greater multiplicity of ethnic groups living in Oslo 
compared with the source population. The F5 rs6025 and F2 rs1799963 polymorphisms 
which increase the risk of pregnancy related VT approximately 5- and 9-fold, 
respectively124;127 are rarely detected in other populations than Caucasians. The larger 
proportion of non-Caucasians in the control group might have underestimated the results 
regarding F5 rs6025 and F2 rs1799963 polymorphisms. Deficiencies of AT, PC and PS
Eligible Cases Eligible  Controls
Risk factors Not participating 
N=215
Participating
N=313
Participating
N=353
Not participating
N=736
% % % %
Antenatal VT 50 50 na na
Postnatal VT 50 50 na na
Age (years)   17-24 24.3 15.7 4.8 16.6
                      25-29 34.4 30.4 26.1 31.7
                      30-34 23.9 34.2 37.7 29.6
                      35-54 17.4 19.8 31.4 22.1
Parity               0 52.3 55.9 49.9 49.5
                         1 26.6 28.8 39.7 29.1
                         2 12.4 12.5 8.2 14.7
                       3 8.7 2.9 2.3 6.6
ART 2.8 5.8 2.3 1.5
Cigarett smokers 28.9 19.8 9.9 15.0
Immobilization 5.0 7.7 0.8 1.1
BMI  >25 30.2 27.1 17.8 22.6
Weight gain < 7.0 kg* 14.2 11.8 8.2 8.4
                    7-21 kg** 47.7 44.7 53.8 50.6
               >21.0 kg*** 38.1 43.5 38.0 41.0
Premature rupture of 
membranes 2.3 1.9 0.3 2.8
Placenta abruption 2.3 1.6 0.8 0.9
Caesarian section  32.6 31.0 21.0 19.4
Bleeding  >1000 ml 13.3 13.4 2.0 4.2
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have been reported to be more common related to VT in Caucasian, but these 
observations might be biased by the more intensively investigation of the Caucasian 
population129. Moreover, the incidence of first time VT is higher in African-Americans 
and lower in Hispanics and Asians as compared with Caucasians130.
Taken these assessments about the study population presented in this thesis into 
consideration, we do believe our results on the risk of pregnancy-related VT for 
hemostatic factors are generalizable for a Caucasian population of pregnant and 
postpartum women. 
5.1.2. Measurements  
Blood samples and analyzes 
Two sets of blood samples, including one collected during index pregnancy VT, might
have given us valuable information whether abnormalities of the hemostatic parameters 
were sustained over time. Furthermore, two sets of blood samples at least 12 weeks apart 
would have given us the possibility to diagnose APS in women with positive APAs. 
In our study design blood sampling was performed at a single time point and several 
years after index pregnancy. The levels of coagulation and fibrinolytic factors return to 
non-pregnant values within 3-6 weeks after delivery108. The time it takes for 
normalization of coagulation factors after an acute VT is more uncertain. Persistent low
or high levels of coagulation factors 3-16 years after an episode of VT are unlikely. We
have reason to believe that hemostatic parameters normalize to pre-pregnant values after 
pregnancy107;131 and we do not have reason to believe that transient elevation of the 
hemostatic variables or false positive or negative tests should be different among cases 
and controls 3-16 years after index pregnancy. In conclusion, we believe blood sampling 
at a single time point and several years after index pregnancy provide valid information 
on the role of the variables analyzed as sustained risk factors for VT.
We minimized potential pre-analytical variables and thereby strengthened the validity of 
our results by using a few dedicated and experienced persons for blood sampling, keeping 
blood samples in room temperature before centrifugation, centrifugation within 1 h after 
venepuncture and aliquotation and freezing the samples shortly after centrifugation. 
Platelet poor plasma (< 10Â109 /L) was used for all the analyses. The frozen blood 
samples have been thawed only once. 
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Thrombin generation assay 
The thrombogram is dependent on so-called assay determinants such as the source and 
concentration of TF used to trigger coagulation and pre-analytical variables. When low 
TF concentration (<1 nM) is used to trigger coagulation, the system is more sensitive to 
coagulation factors involved in the contact pathway of coagulation, whereas for higher TF 
concentrations the thrombogram becomes more dependent on the TF pathway. To trigger 
coagulation we used an intermediate concentration of TF which creates a system sensitive 
for free TFPI and free PS31. As we tested the functionality of the PC system by probing 
the reactions with aPC, the thrombogram became sensitive to free PS antigen, free TFPI 
and fX40.
A potential pre-analytical variable in thrombin generation assays is activation of the 
contact pathway. An option to avoid contact activation is to add corn trypsin inhibitor 
(CTI) to the blood sample tubes before venous puncture, as we did not. A recent 
published study showed that addition of CTI was not needed if coagulation was trigged
by TF concentrations was above 1 pM and caution was paid to pre-analytical 
variables132.
Median n-aPC-sr in our controls was lower than expected, i.e. lower than 1, which means 
that our PNP was less sensitive to aPC than plasma from the controls. Differences in 
preparing PNP and preparing single plasmas may explain the more aPC resistant PNP as 
compared with plasma from the controls. When preparing PNP, plasmas from both men 
and women were mixed and furthermore, the time between centrifugation and freezing 
was delayed compared to the time spent when preparing single plasmas. We have used 
the same PNP in all analyzes and have no reason to doubt that our results are valid. 
Antiphospholipid antibodies 
Variability on detection of APAs and determination of cut-offs are known challenges 
concerning the laboratory classification criteria for APS. We analyzed aCL- and anti-
ȕ2GP 1 antibodies based on methods and cut-offs described by the 2006 Sidney update of 
the classification criteria for APS54, and LAs was mainly detected as described by Brandt 
et al in 199556.
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For the detection of LAs we used assays integrating screening and confirmatory steps and 
1:1 mixing of test plasma and PNP. The use of integrated assays increase sensitivity and 
specificity compared to the use of separate assays133 and the results were normalized 
against results from PNP run in parallel.
Questionnaire 
Information from the questionnaire that was completed at time of blood sampling has not 
been a source for main analyzes in any of the three papers included in the present thesis. 
Information from the questionnaire has been used to investigate 1) clinical characteristics 
at time of blood sampling such as morbidity, age, BMI, daily cigarette smoking and parity 
that might influence the variables analyzed, 2) the association between pregnancy-related 
VT and different hemostatic factors in the absence and presence of women who were 
pregnant, used oral contraceptives or anticoagulation at time of blood sampling and 3) 
information on the use of daily medications other than anticoagulation therapy. 
5.1.3. Statistical aspects 
Pre-study power calculations were done for the original VIP-study, but not for hemostatic 
variables as investigations of these variables were sub-studies of the original study. 
However, we performed post-hoc power analysis for the ability to detect differences in 
prevalence of the hemostatic variables analyzed. If we expected 10% of the controls to 
have a risk factor, and 20% of the cases to have the same risk factor, our material was
estimated to have a test power of 95%. The test power increased to 99.9% if 10% of the 
controls had the exposure and 30% of the cases. For rare exposures such as deficiencies 
of the natural anticoagulants, our population was too small to calculate risk of VT. 
The distribution of n-aPC-sr was relatively skewed and in Paper I we interpreted the 
residuals to be close enough to normal distribution to use parametric methods in the 
statistical analysis. In paper II we categorized n-aPC-sr into quartiles and percentiles.
Similar to other studies assessing the risk of VT for hemostatic factors84;88;91;134-136 we 
defined high or low levels of the hemostatic variables by defining percentiles in the 
control group. This is not a method to screen for deficiencies of pro-or anticoagulant 
coagulation factors, but a way to investigate whether or not high or low levels of the 
hemostatic variables are associated with VT. 
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5.2. Discussion of main findings 
All three papers included in the present thesis describe different biological risk factors 
for pregnancy-related VT, paper I additionally explore differential risk factor for DVT 
and PE. We have confirmed that risk factors for VT in the general population are risk 
factors also for pregnancy-related VT. Although it is impossible to directly compare 
risk for VT between different studies as laboratory assays and cut-offs are different, our 
risk estimates for pregnancy-related VT are mainly similar to risk estimates for VT in 
the general population. Our studies give valuable insight about the pathophysiology of 
pregnancy-related VT, and of special interest is our data concerning differential risk 
factors for pregnancy-related PE and DVT. 
Similar to the acute phase reactant C-reactive protein (CRP), plasma levels of several 
coagulation factors are influenced by ongoing inflammation. High-sensitivity CRP (hs-
CRP) is a sensitive method to measure low levels of CRP. We evaluated whether 
abnormal levels of coagulation parameters described in paper I were caused by 
inflammation by statistically controlling the coagulation parameters for hs-CRP.  
5.2.1. Hemostatic factors associated with pregnancy-related venous thrombosis 
Elevated levels of fVIII is an established risk factor for VT in the general-
population84;134;137. We describe for the first time elevated levels of fVIII as an 
independent risk factor for pregnancy-related VT, not influenced by an ongoing 
inflammation or the sequelae after the VT itself. Similar to us, Kamphuisen et al 
described fVIII as an independent risk factor in the population-based Leiden 
Thrombophilia Study138.
The determinants of elevated plasma levels of fVIII are largely unknown139. Bank et al 
found elevated levels of fVIII in near one-half of first-degree relatives of patients with VT 
and suggested a genetic basis of elevated plasma fVIII activity140. Other known 
determinants of fVIII plasma levels are von Willebrand factor (VWF) and the AB0 blood 
group141. We did not analyze VWF or the AB0 blood groups, so we don’t know whether 
these variables would affect the association between fVIII and VT in our study, but 
previous reports have shown that corrections for VWF and AB0-blood groups did not 
change the relation between fVIII and the risk for VT84;137.
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The mechanism by which elevated levels of fVIII exerts its thrombotic effect is unclear. 
One explanation may be that elevated levels of fVIII lead to increased activation of fX 
resulting in excessive thrombin formation. High levels of fVIII have recently been shown 
to mediate enhancement of thrombin generation142. Another mechanism may be that high 
levels of fVIIIa override the anticoagulant effect of aPC and thereby increase the 
susceptibility to VT. High levels of fVIII has been shown to enhance the aPC resistant 
phenotype in carriers of F5 rs6025143. Furthermore, the Leiden Thrombophilia Study 
found a high correlation between high levels of fVIII and reduced sensitivity to aPC144.
Finally, a recent report from two population-based case-controls studies showed that 
increased risk of VT in people with increased BMI was partly explained by fVIII induced 
aPC resistance145. We did not control for BMI as BMI was evenly distributed between the 
cases and the controls. 
To our knowledge we are the first to describe independent associations between elevated 
levels of n-ETP and D-dimer and pregnancy-related VT. Similar associations between 
ETP and D-dimer and risk of VT have been described in the general population in the 
Leiden Thrombiphilia Study135;146. Lowe et al found increased risk of VT in elderly 
women with increased levels of D-dimer147. Increased levels of theses global hemostatic 
parameters several years after index pregnancy may reflect a sustained activation of the 
coagulation system in these individuals, making them more susceptible to VT.
5.2.2. Reduced sensitivity to activated protein C 
APC resistance is the phenotypic expression of the F5 rs6025 polymorphism30. We 
investigated reduced sensitivity to aPC and the risk for pregnancy-related VT in two 
separate groups; in non-carriers and in carriers of the F5 rs6025 polymorphisms. To 
investigate the effect of aPC resistance on the risk of pregnancy-related VT in absence of 
known contributors to aPC resistance, we excluded women who were pregnant or used 
oral contraceptives at time of blood sampling.
Analyzing only non-carriers of F5 rs6025 polymorphism, women who had n-aPC-sr in 
the 4th quartile had a three-fold increased risk of pregnancy-related VT as compared with 
women with n-aPC-sr in the 1st quartile. Apart from the study presented in this thesis, 
there has, to our knowledge, been only one publication on aPC resistance in absence of 
F5 rs6025 and pregnancy-related VT and they did not find an association between 
reduced sensitivity to aPC and pregnancy-related VT148. Our results presumably differ 
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because they used an aPTT-based method to analyze the function of the PC system, and 
their sample size was relatively small.
When we analyzed women carrying the F5 rs6025 polymorphism, we found near a 4 
times increased risk of VT in women with high levels of n-aPC-sr as compared with 
carriers with lower levels of n-aPC-sr. Although not statistically significant, there was a
clear dose-response relationship between an aPC resistant phenotype and the risk of VT 
in carriers of F5 rs6025, suggesting that even in carriers of F5 rs6025, the degree of aPC 
resistance is an important determinant of the risk of VT.  
Given the complexity of the protein C system, there are multiple possible explanations for 
the association between aPC resistance and increased risk of VT. We found that PC, free 
PS antigen and free TFPI were negatively correlated with n-aPC-sr in absence of F5 
rs6025, but only free PS antigen was associated with pregnancy-related VT. When we 
adjusted n-aPC-sr for free PS antigen in non-carriers of F5 rs6025, the association 
between n-aPC-sr and VT was not lost, indicating that reduced sensitivity to aPC and 
increased risk for pregnancy-related VT was not explained by low levels of free PS 
antigen. In our population, n-aPC-sr was not correlated with fVIII. Single gene mutations 
in the F5 gene apart from F5 rs6025 polymorphism or subtle regulation of multiple 
clotting factor or inhibitor genes may be mechanisms responsible for aPC resistance in 
absence of F5 rs6025.
5.2.3. Anti-phospholipid antibodies 
As described in paper III we did not find an association between having at least one 
positive test for APAs and pregnancy-related VT. However, we found that 9 cases and 
none controls were positive for at least two APAs. When we excluded women with IgM 
antibodies, still 7 cases were APA multi-positive.  
The prevalence of APAs depends on the definition of a positive test. We used the 99th
percentile defined in the control group as reference for each of the 6 APA assays, and 
thereby 1% of the controls had positive results for each test. In our study, 6.8% of the 
controls were positive for at least one APA, which is a result of the definition of cut-offs.
Utilizing the 99.7th percentile as cut off, 4.8% (15/313) of the cases and 1.7% (6/353) of 
the controls were positive for any APA, whereas 9.3% (29/313) of the cases and 6.8% 
(24/353) of the controls were APA positive when the 99th percentile was used as cut-off.
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This finding shows that a higher percentage of the APA-positive cases as compared with 
controls were still positive for any APA when we increased the cut-off level, which 
indicate that the cases had higher APA titers. Increasing the cut-off would probably 
increase the specificity of the tests, possible at the cost of decreasing the tests sensitivity.
We used cut-off levels as suggested by the 2006 APS consensus report54.
Beside titer levels, the number of positive APA tests is important for the risk of VT. It is 
now believed that ȕ2GP1 is the main antigen for APAs and a substantial part of anti-
ȕ2GP1 antibodies have LA activity and are aCL positive51;52. In paper III we applied the 
statements of the 2006 APS consensus report54, which assigned the same role and 
importance for each of the three types of APAs when deciding cut-offs and interpreting
results. Over the last years the understanding of the importance of APA multi-positivity 
has been enlightened and several studies have shown that triple APA positivity are more 
strongly associated with thrombosis than the presence of single or double positivity57;149-
152. Of notice, the association between APA multi-positivity and VT involve the IgG 
isotype, whereas the clinical relevance of the IgM isotype is unsettled153. We only found 
APA multi-positivity among the cases in this population of otherwise healthy women and 
with a long time range between the thrombotic event and blood sampling. When we 
excluded women with IgM antibodies (aCL and anti-ȕ2GP1), still 7 women were APA 
multi-positive. Our data confirm the importance of APA multi-positivity and risk of VT. 
As venipuncture was performed only once we don’t know if any of these APA multi-
positive women fulfilled the criteria for APS.
5.2.4. Differential risk factors for pregnancy-related DVT and PE 
The possibility of DVT and PE being partly different diseases are interesting concerning 
the understanding of the pathophysiology of VT and it would have important clinical 
implications regarding risk assessments and treatment. Therefore we investigated 
potential differential risk factors for pregnancy-related DVT and PE.
A recent systematic review found several risk factors for VT that had differential risk for 
DVT and PE, but reports on separate risks for DVT and PE for coagulation factors or the 
natural anticoagulants were not found106. The authors concluded that DVT and PE not 
always should be considered as two presentations of the same disease. 
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Hemostatic factors associated with increased risk of PE 
After adjusting for hsCRP, fIX above the 90th percentile was no longer associated with 
pregnancy-related VT, but the risk for PE was more than doubled as compared with 
controls. For women with free PS antigen at or below 65% the risk of PE was increased 3 
times as compared with controls. The risk of DVT as compared with controls for high 
levels of fIX or low levels of free PS antigen was not significantly increased. Differential 
risk for PE and DVT for abnormal levels of fIX and free PS antigen has not previously 
been reported and need to be confirmed in other studies. Interestingly, in a family study, 
Zoller et al found to their surprise that individuals with a combination of PS deficiency 
and a polymorphism in the PAI-1 promotor gene had increased risk of PE, whereas the 
risk for DVT was not increased154.
We found that high levels of fibrinogen increased the risk of PE, whereas the risk for 
DVT was not increased. The association might partly be explained by a concomitant 
inflammation at time of blood sampling as the risk was lowered and no longer statistical 
significant when we adjusted for hsCRP. On the other hand, this adjustment might hide an 
interesting effect as chronic low-grade inflammation in these women might lead to 
elevated levels of fibrinogen which increase the risk of VT. 
The association between high levels of fibrinogen and PE may be explained by clot 
structure as fibrinogen levels have been shown to be a predictor of the clot architecture155.
Structural integrity of the clot is provided by fibrin and reduced clot stability might 
dispose for embolization. Homozygous carriers of the Ala allele in the Į-fibrinogen 
Thr312Ala polymorphism, a common genetic variant, have been shown to have increased 
risk for PE156. The Thr312Ala polymorphisms might influence fibrin cross-linking and 
thereby clot stability, making the clot more unstable and susceptible to embolization. To 
further explore this finding the same group investigated clot formation and structure in an 
in vitro system for both Thr312 and Ala312, and they found that the Į-fibrinogen 
Thr312Ala polymorphism affects clot structure and stiffness157.
Hemostatic factors associated with increased risk of DVT 
Reduced sensitivity to aPC in non-carriers of F5 rs6025 polymorphism and carriers of F5 
rs6025 had increased risk of pregnancy-related DVT, whereas the risk for PE was not
increased. APC resistant phenotype appears to be the key mechanism in the different 
presentations of DVT and PE. As initially suggested in 1996101 it seems that the «factor V 
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Leiden paradox» in fact is an “aPC-resistant paradox». Van Langevelde et al106 found in 
their systematic review a stronger effect on DVT than PE for women using combined oral 
contraceptives and for pregnant women. The association between reduced sensitivity to 
aPC and use of oral contraceptives and pregnancy presented in paper II support their 
proposal that the increased risk of DVT in oral contraceptive users and in pregnancy 
might be explained by acquired aPC resistance. 
To investigate possible mechanisms behind the different presentations of DVT and PE in 
carriers of F5 rs6025, van Stralen et al studied differences in the location of VT, the 
number of affected veins, the time between provocation of thrombus formation and the 
actual diagnosis, growth speed of the thrombus and last, clot structure in carriers and non-
carriers of the F5 rs6025 polymorphisms158. They confirmed the factor V Leiden paradox, 
but none of the investigated candidates to explain the phenomenon were explanatory.
APC has in an in vitro system shown to have indirect pro-fibrinolytic effects, mainly by 
reducing thrombin formation and thereby indirectly inhibit TAFI activation159. Increased 
levels of TAFI have been found in aPC resistant patients160. APC resistance promotes 
sustained thrombin generation and thereby stimulate TAFI activation and subsequent 
inhibition of fibrinolysis, which increases clot stability161. Hypothetically, increased TAFI 
activation and more stable clots might partly explain the increased risk of DVT in aPC 
resistant individuals. In a case report of a 45 year old woman with aPC resistance and 
who experienced several episodes of DVT in both legs, the pro-fibrinolytic effect of aPC 
was markedly reduced162.
5.2.5. Clinical implications 
Our reports on hemostatic risk factors associated with increased risk for pregnancy-
related VT and differential risk of DVT and PE are pieces in the puzzle of the
understanding of the mechanisms of VT, in particular pregnancy-related VT.
Furthermore, our findings challenge the opinion that DVT and PE are two manifestations 
of the same disease. Improved understanding of the mechanisms of VT, and DVT and PE,
is the key to be able to recognize who are at risk of VT and especially at risk of PE. A 
better understanding of the mechanisms of VT is necessary for improving treatment and 
prophylaxis of VT. Studying pregnancy-related VT itself is important as it increases the 
awareness of the disease.
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We have investigated risk factors for pregnancy-related VT, but whether patients with VT 
or individuals with a family history of VT should be screened for thrombophilia is 
controversial, and our study does not try to give an answer to this question. 
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6. Conclusions  
The studies included in this thesis explored the association between hemostatic 
biomarkers and a history of a first lifetime VT during pregnancy or the postpartum, and 
we found that known risk factors for VT in the general population were risk factors for 
pregnancy-related VT. We also investigated differential risk for pregnancy-related DVT 
and PE for hemostatic parameters, and our data strengthen the hypothesis of differential
pathophysiology between DVT and PE. Having in mind the possible selection bias of the 
present studies, our results must be interpreted with caution. Still, our conclusions are as 
follows:  
x High levels of fVIII, n-ETP and D-dimer are risk factors for pregnancy-related 
VT.
x Women with inherited aPC resistance and women with reduced sensitivity to aPC 
in absence of factor V Leiden have increased risk of pregnancy-related DVT,
whereas women with high levels of fIX or low levels of free PS antigen have
increased risk of PE.
x Reduced sensitivity to aPC in absence of factor V Leiden was a risk factor for 
pregnancy-related, and an aPC resistant phenotype was related to increased risk of 
VT in carriers of factor V Leiden. 
x APA multi-positivity was highly associated with pregnancy-related VT. 
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7. Future perspectives 
Pregnancy-related VT is relatively rare, but as it is a major cause of increased morbidity 
and mortality in young women, a future goal must be to decrease the incidence of VT 
during pregnancy and postpartum. How can this goal be reached? First of all it is 
important that doctors are aware of the risk of pregnancy-related VT, and especially the 
increased risk of PE at the end of the third trimester and the first 3 weeks postpartum.
Shortness of breath is not always explained by pregnancy or being an exhausted mother.
To identify women at risk of pregnancy-related VT it is essential to know about the risk 
factors, and to increase our knowledge about the risk factors of pregnancy-related VT, we 
must understand the pathophysiology of VT. Much of the knowledge of the mechanisms 
of VT is based on mechanisms of arterial thrombosis. Little is for example known about 
the contribution of venous endothelial cells in the development of VT, and further 
investigations are needed to explore the PC anticoagulant pathways in VT. Increased 
knowledge about the interactions between venous endothelial cells and pro-and 
anticoagulant pathways may enlighten the understanding why some VTs embolize and 
others do not. Clot structure and fibrinolysis probably also play a central in the 
understanding of why some thrombi embolize and this need to be further investigated. 
The association between PE and high levels of fIX and low levels of free PS antigen 
needs to be confirmed in other studies. Likewise, the relation between F5 rs6025 
polymorphism and aPC resistant phenotype and risk of VT needs to be further 
investigated.
To better compare reports on risk factors of VT, standardization of laboratory assays and 
standardization of cut-off values are needed. 
62
8.References 
 
1. Owren PA. Parahaemophilia; haemorrhagic diathesis due to absence of a 
previously unknown clotting factor. Lancet 1947;1:446-448.
2. Ratnoff OD, Davie EW. The activation of Christmas factor (factor IX) by 
activated plasma thromboplastin antecedent (activated factor XI). Biochemistry 
(Mosc). 1962;1:677-685.
3. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its
function as a biochemical amplifier. Nature 1964;202:498-499.
4. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 
1964;145:1310-1312.
5. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue 
factor and factor VII: additional pathway for initiating blood coagulation. 
Proc.Natl.Acad.Sci.U.S.A 1977;74:5260-5264.
6. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links 
platelets, coagulation, and inflammation. Blood 2012;119:5972-5979.
7. Colman RW, Schmaier AH. The contact activation system: biochemistry and 
interactions of these surface-mediated defense reactions. Crit Rev.Oncol.Hematol. 
1986;5:57-85.
8. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic 
systems. Int.J.Hematol. 2004;79:103-108.
9. Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional 
thrombin receptor. Issues and opportunities. J.Clin.Invest 1992;89:351-355.
10. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor 
pathway to thrombin. I. An empirical study. J.Biol.Chem. 1994;269:23357-23366.
11. Bishop P, Lawson J. Recombinant biologics for treatment of bleeding disorders. 
Nat.Rev.Drug Discov. 2004;3:684-694.
12. Dahlback B. Blood coagulation. Lancet 2000;355:1627-1632.
13. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor 
VIIIa in the activation of bovine factor X. J.Biol.Chem. 1981;256:3433-3442.
14. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. 
Semin.Hematol. 1992;29:213-226.
15. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and 
Factor Va to the activity of prothrombinase. J.Biol.Chem. 1979;254:10952-10962.
63
16. Mosnier LO, Lisman T, van den Berg HM et al. The defective down regulation of 
fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma 
concentration. Thromb.Haemost. 2001;86:1035-1039.
17. Mann KG, Brummel K, Butenas S. What is all that thrombin for? 
J.Thromb.Haemost. 2003;1:1504-1514.
18. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor 
VIIa-dependent coagulation in hemophilia blood. Blood 2002;99:923-930.
19. Suenson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis 
of a positive feed-back mechanism in fibrinolysis. Eur.J.Biochem. 1984;140:513-
522.
20. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. 
Semin.Thromb.Hemost. 1987;13:50-68.
21. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic 
potential is a risk factor for venous thrombosis. Blood 2005;105:1102-1105.
22. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor--the key to feedback 
control of blood coagulation initiated by tissue thromboplastin. Haemostasis 
1991;21:219-239.
23. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and 
uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods 
Enzymol. 1993;222:525-559.
24. Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C 
anticoagulant pathway: novel insights into structure-function relationships and 
molecular recognition. Arterioscler.Thromb.Vasc.Biol. 2005;25:1311-1320.
25. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the 
tissue factor pathway by tissue factor pathway inhibitor. 
Proc.Natl.Acad.Sci.U.S.A. 2006;103:3106-3111.
26. Hackeng TM, Maurissen LF, Castoldi E, Rosing J. Regulation of TFPI function 
by protein S. J.Thromb.Haemost. 2009;7 Suppl 1:165-168.
27. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. 
J.Thromb.Haemost. 2010;8:445-453.
28. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously 
unrecognized mechanism characterized by poor anticoagulant response to 
activated protein C: prediction of a cofactor to activated protein C. 
Proc.Natl.Acad.Sci.U.S.A 1993;90:1004-1008.
29. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V 
gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance 
to activated protein C. J.Clin.Invest 1994;94:2521-2524.
64
30. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V 
associated with resistance to activated protein C. Nature 1994;369:64-67.
31. de Visser MC, van Hylckama Vlieg A, Tans G et al. Determinants of the APTT -
and the ETP - based APC sensitivity tests. Journal of Thrombosis and 
Haemostasis 2005;3:1488-1494.
32. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological 
observations of thrombo-embolic disease during pregnancy and in the puerperium, 
in 56,022 women. Int.J.Gynaecol.Obstet. 1983;21:327-331.
33. Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. 
Am.J.Obstet.Gynecol. 1999;180:S375-S382.
34. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone 
replacement therapy and acquired resistance to activated protein C: results of a 
randomized, double-blind, placebo-controlled trial. Br.J.Haematol. 2001;115:415-
420.
35. Falanga A. The incidence and risk of venous thromboembolism associated with 
cancer and nonsurgical cancer treatment. Cancer Invest 2009;27:105-115.
36. Tchaikovski SN, Thomassen MC, Costa SD, Peeters LL, Rosing J. Role of protein 
S and tissue factor pathway inhibitor in the development of activated protein C 
resistance early in pregnancy in women with a history of preeclampsia. 
Thromb.Haemost. 2011;106:914-921.
37. van Vliet HA, Bertina RM, Dahm AE et al. Different effects of oral contraceptives 
containing different progestogens on protein S and tissue factor pathway inhibitor. 
J.Thromb.Haemost. 2008;6:346-351.
38. Curvers J, Thomassen MC, Nicolaes GA et al. Acquired APC resistance and oral 
contraceptives: differences between two functional tests. Br.J.Haematol. 
1999;105:88-94.
39. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation 
measurement in clotting plasma. Pathophysiology of Haemostasis and Thrombosis 
2003;33:4-15.
40. Castoldi E, Rosing J. Thrombin generation tests. Thromb.Res. 2011;127 Suppl 
3:S21-S25.
41. Besser M, Baglin C, Luddington R, Van Hylckama Vlieg A, Baglin T. High rate 
of unprovoked recurrent venous thrombosis is associated with high thrombin-
generating potential in a prospective cohort study. Journal of Thrombosis and 
Haemostasis 2008;6:1720-1725.
42. Dielis AW, Castoldi E, Spronk HM et al. Coagulation factors and the protein C 
system as determinants of thrombin generation in a normal population. 
J.Thromb.Haemost. 2008;6:125-131.
65
43. Rosenkranz A, Hiden M, Leschnik B et al. Calibrated automated thrombin 
generation in normal uncomplicated pregnancy. Thromb.Haemost. 2008;99:331-
337.
44. Tchaikovski SN, van Vliet HA, Thomassen MC et al. Effect of oral contraceptives 
on thrombin generation measured via calibrated automated thrombography. 
Thromb.Haemost. 2007;98:1350-1356.
45. Curvers J, Christella M, Thomassen LG et al. Effects of (pre-)analytical variables 
on activated protein C resistance determined via a thrombin generation-based 
assay. Thromb.Haemost. 2002;87:483-492.
46. Liestol S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance 
determined with a thrombin generation-based test is associated with thrombotic 
events in patients with lupus anticoagulants. J.Thromb.Haemost. 2007;5:2204-
2210.
47. Dargaud Y, Luddington R, Gray E et al. Effect of standardization and 
normalization on imprecision of calibrated automated thrombography: an 
international multicentre study. Br.J.Haematol. 2007;139:303-309.
48. Dargaud Y, Wolberg AS, Luddington R et al. Evaluation of a standardized 
protocol for thrombin generation measurement using the calibrated automated 
thrombogram: An international multicentre study. Thromb.Res. 2012
49. de Groot PG, Lutters B, Derksen RH et al. Lupus anticoagulants and the risk of a 
first episode of deep venous thrombosis. J.Thromb.Haemost. 2005;3:1993-1997.
50. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A 
prospective study of anticardiolipin antibodies as a risk factor for venous 
thrombosis in a general population (the HUNT study). J.Thromb.Haemost. 
2006;4:44-49.
51. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein 
I-dependent lupus anticoagulant highly correlates with thrombosis in the 
antiphospholipid syndrome. Blood 2004;104:3598-3602.
52. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize 
epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their 
presence correlates strongly with thrombosis. Blood 2005;105:1540-1545.
53. Pierangeli SS, Chen PP, Raschi E et al. Antiphospholipid antibodies and the 
antiphospholipid syndrome: pathogenic mechanisms. Semin.Thromb.Hemost. 
2008;34:236-250.
54. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an 
update of the classification criteria for definite antiphospholipid syndrome (APS). 
J.Thromb.Haemost. 2006;4:295-306.
55. de Groot PG, Urbanus RT. The significance of autoantibodies against beta2-
glycoprotein I. Blood 2012;120:266-274.
66
56. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus 
anticoagulants: results of the Second International Workshop for Identification of 
Lupus Anticoagulants. On behalf of the Subcommittee on Lupus 
Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb.Haemost. 
1995;74:1597-1603.
57. Pengo V, Ruffatti A, Legnani C et al. Incidence of a first thromboembolic event in 
asymptomatic carriers of high-risk antiphospholipid antibody profile: a 
multicenter prospective study. Blood 2011;118:4714-4718.
58. Naess IA, Christiansen SC, Romundstad P et al. Incidence and mortality of 
venous thrombosis: a population-based study. J.Thromb.Haemost. 2007;5:692-
699.
59. Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Br.J.Haematol. 
2006;134:357-365.
60. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. 
N.Engl.J.Med. 2011;364:351-360.
61. Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte 
Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Staatsdruckerei 1856
62. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous 
thrombosis. Lancet 2010;376:2032-2039.
63. Aird WC. Spatial and temporal dynamics of the endothelium. J.Thromb.Haemost. 
2005;3:1392-1406.
64. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-
1173.
65. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep 
vein thrombosis: incidence and risk factors. Arch.Intern.Med. 2000;160:769-774.
66. Reitsma PH. Genetic heterogeneity in hereditary thrombophilia. Haemostasis 
2000;30 Suppl 2:1-10.
67. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin deficiency in the 
healthy population. Br.J.Haematol. 1994;87:106-112.
68. Tait RC, Walker ID, Reitsma PH et al. Prevalence of protein C deficiency in the 
healthy population. Thromb.Haemost. 1995;73:87-93.
69. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. 
N.Engl.J.Med. 2001;344:1222-1231.
70. Koster T, Rosendaal FR, Briet E et al. Protein C deficiency in a controlled series 
of unselected outpatients: an infrequent but clear risk factor for venous thrombosis 
(Leiden Thrombophilia Study). Blood 1995;85:2756-2761.
67
71. Martinelli I, Mannucci PM, de Stefano V et al. Different risks of thrombosis in 
four coagulation defects associated with inherited thrombophilia: a study of 150 
families. Blood 1998;92:2353-2358.
72. Bucciarelli P, Rosendaal FR, Tripodi A et al. Risk of venous thromboembolism 
and clinical manifestations in carriers of antithrombin, protein C, protein S 
deficiency, or activated protein C resistance: a multicenter collaborative family 
study. Arterioscler.Thromb.Vasc.Biol. 1999;19:1026-1033.
73. Middeldorp S, Levi M. Thrombophilia: an update. Semin.Thromb.Hemost. 
2007;33:563-572.
74. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 
1995;346:1133-1134.
75. Koster T, Rosendaal FR, de Ronde H et al. Venous thrombosis due to poor 
anticoagulant response to activated protein C: Leiden Thrombophilia Study. 
Lancet 1993;342:1503-1506.
76. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis
in patients homozygous for factor V Leiden (activated protein C resistance). 
Blood 1995;85:1504-1508.
77. Rosendaal FR, Doggen CJ, Zivelin A et al. Geographic distribution of the 20210 
G to A prothrombin variant. Thromb.Haemost. 1998;79:706-708.
78. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation 
in the 3'-untranslated region of the prothrombin gene is associated with elevated 
plasma prothrombin levels and an increase in venous thrombosis. Blood 
1996;88:3698-3703.
79. Saemundsson Y, Sveinsdottir SV, Svantesson H, Svensson PJ. Homozygous 
factor V Leiden and double heterozygosity for factor V Leiden and prothrombin 
mutation. J.Thromb.Thrombolysis. 2012
80. Martinelli I, Bucciarelli P, Margaglione M et al. The risk of venous 
thromboembolism in family members with mutations in the genes of factor V or 
prothrombin or both. Br.J.Haematol. 2000;111:1223-1229.
81. Vossen CY, Hasstedt SJ, Rosendaal FR et al. Heritability of plasma 
concentrations of clotting factors and measures of a prethrombotic state in a 
protein C-deficient family. J.Thromb.Haemost. 2004;2:242-247.
82. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The 
value of family history as a risk indicator for venous thrombosis. 
Arch.Intern.Med. 2009;169:610-615.
83. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus 
on venous thrombosis. Thromb.Haemost. 1997;78:1-6.
68
84. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting 
factor VIII in effect of von Willebrand factor on occurrence of deep-vein 
thrombosis. Lancet 1995;345:152-155.
85. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. 
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 
2005;293:2352-2361.
86. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High 
levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-
3682.
87. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: 
American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines (8th Edition). Chest 2008;133:381S-453S.
88. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High 
levels of coagulation factor XI as a risk factor for venous thrombosis. 
N.Engl.J.Med. 2000;342:696-701.
89. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated 
with the risk of deep venous thrombosis mainly in the elderly. J.Thromb.Haemost. 
2003;1:2677-2678.
90. Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. 
Thromboprophylaxis with low-molecular-weight heparin in outpatients with 
plaster-cast immobilisation of the leg. Lancet 1995;346:459-461.
91. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis 
inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855-2859.
92. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for 
venous thrombosis. Arch.Intern.Med. 2008;168:21-26.
93. Dahm A, van Hylckama Vlieg A, Bendz B et al. Low levels of tissue factor 
pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 
2003;101:4387-4392.
94. den HM, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for 
deep-vein thrombosis. N.Engl.J.Med. 1996;334:759-762.
95. Bergrem A, Dahm AE, Jacobsen AF et al. Resistance to activated protein C is a 
risk factor for pregnancy-related venous thrombosis in the absence of the F5 
rs6025 (factor V Leiden) polymorphism. Br.J.Haematol. 2011;154:241-247.
96. Gibbs NM. Venous thrombosis of the lower limbs with particular reference to 
bed-rest. Br.J.Surg. 1957;45:209-236.
97. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous 
thromboembolism. Am.J.Med. 2005;118:978-980.
69
98. Hoibraaten E, Qvigstad E, Arnesen H et al. Increased risk of recurrent venous 
thromboembolism during hormone replacement therapy--results of the 
randomized, double-blind, placebo-controlled estrogen in venous 
thromboembolism trial (EVTET). Thromb.Haemost. 2000;84:961-967.
99. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. 
Hematology.Am.Soc.Hematol.Educ.Program. 20051-12.
100. Lee AY, Kamphuisen PW. Epidemiology and prevention of catheter-related 
thrombosis in patients with cancer. J.Thromb.Haemost. 2012
101. Desmarais S, de Moerloose P, Reber G et al. Resistance to activated protein C in 
an unselected population of patients with pulmonary embolism. Lancet 
1996;347:1374-1375.
102. Makelburg AB, Veeger NJ, Middeldorp S et al. Different risk of deep vein 
thrombosis and pulmonary embolism in carriers with factor V Leiden compared 
with non-carriers, but not in other thrombophilic defects. Results from a large 
retrospective family cohort study. Haematologica 2010;95:1030-1033.
103. Meyer G, Emmerich J, Helley D et al. Factors V leiden and II 20210A in patients 
with symptomatic pulmonary embolism and deep vein thrombosis. Am.J.Med. 
2001;110:12-15.
104. Margaglione M, Brancaccio V, de Lucia D et al. Inherited thrombophilic risk 
factors and venous thromboembolism: distinct role in peripheral deep venous 
thrombosis and pulmonary embolism. Chest 2000;118:1405-1411.
105. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of 
factor V Leiden and prothrombin G20210A mutations in unselected patients with 
venous thromboembolism. Br.J.Haematol. 2000;110:125-129.
106. van Langevelde K., Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, 
Cannegieter SC. Broadening the factor V Leiden paradox: pulmonary embolism 
and deep-vein thrombosis as two sides of the spectrum. Blood 2012
107. Bremme KA. Haemostatic changes in pregnancy. Best.Pract.Res.Clin.Haematol. 
2003;16:153-168.
108. Dahlman T, Hellgren M, Blomback M. Changes in blood coagulation and 
fibrinolysis in the normal puerperium. Gynecol.Obstet.Invest 1985;20:37-44.
109. Clark P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, 
protein S and coagulation in normal pregnancy. Thromb.Haemost. 1998;79:1166-
1170.
110. Ishii A, Yamada S, Yamada R, Hamada H. t-PA activity in peripheral blood 
obtained from pregnant women. J.Perinat.Med. 1994;22:113-117.
111. Nakashima A, Kobayashi T, Terao T. Fibrinolysis during normal pregnancy and 
severe preeclampsia relationships between plasma levels of plasminogen 
activators and inhibitors. Gynecol.Obstet.Invest 1996;42:95-101.
70
112. Kruithof EK, Tran-Thang C, Gudinchet A et al. Fibrinolysis in pregnancy: a study 
of plasminogen activator inhibitors. Blood 1987;69:460-466.
113. Giavarina D, Mezzena G, Dorizzi RM, Soffiati G. Reference interval of D-dimer 
in pregnant women. Clin.Biochem. 2001;34:331-333.
114. Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in 
pregnancy, during delivery and in the puerperium. I. Normal condition. 
Gynecol.Obstet.Invest 1981;12:141-154.
115. Righini M, Jobic C, Boehlen F et al. Predicting deep venous thrombosis in 
pregnancy: externalvalidation of the "left" clinical prediction rule. Haematologica 
2012
116. Cockett FB, Thomas ML, Negus D. Iliac vein compression.--Its relation to 
iliofemoral thrombosis and the post-thrombotic syndrome. Br.Med.J. 1967;2:14-
19.
117. Martinelli I. Thromboembolism in women. Semin.Thromb.Hemost. 2006;32:709-
715.
118. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous 
thromboembolism in pregnancy and puerperium--a register-based case-control 
study. Am.J.Obstet.Gynecol. 2008;198:233-237.
119. Vandenbroucke JP, Koster T, Briet E et al. Increased risk of venous thrombosis in 
oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 
1994;344:1453-1457.
120. James AH. Venous thromboembolism in pregnancy. 
Arterioscler.Thromb.Vasc.Biol. 2009;29:326-331.
121. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality 
in the United States, 1998 to 2005. Obstet.Gynecol. 2010;116:1302-1309.
122. Hogberg U, Innala E, Sandstrom A. Maternal mortality in Sweden, 1980-1988.
Obstet.Gynecol. 1994;84:240-244.
123. Wildman K, Bouvier-Colle MH. Maternal mortality as an indicator of obstetric 
care in Europe. BJOG. 2004;111:164-169.
124. Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Risk of venous 
thrombosis in pregnancy among carriers of the factor V Leiden and the 
prothrombin gene G20210A polymorphisms. J.Thromb.Haemost. 2010;8:2443-
2449.
125. Martinelli I, de Stefano V, Taioli E et al. Inherited thrombophilia and first venous 
thromboembolism during pregnancy and puerperium. Thromb.Haemost. 
2002;87:791-795.
71
126. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations 
in women with a history of thrombosis during pregnancy and the puerperium. 
N.Engl.J.Med. 2000;342:374-380.
127. Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: a systematic 
review. Br.J.Haematol. 2006;132:171-196.
128. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of 
venous thrombosis: a hospital-based case-control study. Journal of Thrombosis 
and Haemostasis 2008;6:905-912.
129. Montagnana M, Favaloro EJ, Franchini M, Guidi GC, Lippi G. The role of 
ethnicity, age and gender in venous thromboembolism. J.Thromb.Thrombolysis. 
2010;29:489-496.
130. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous 
thromboembolism. Thromb.Res. 2009;123 Suppl 4:S11-S17.
131. Brenner B. Haemostatic changes in pregnancy. Thromb.Res. 2004;114:409-414.
132. Spronk HM, Dielis AW, Panova-Noeva M et al. Monitoring thrombin generation: 
is addition of corn trypsin inhibitor needed? Thromb.Haemost. 2009;101:1156-
1162.
133. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisloff F. The Lupus Ratio 
test--an interlaboratory study on the detection of Lupus anticoagulants by an 
APTT-based, integrated, and semi-quantitative test. Fifth International Survey of 
Lupus Anticoagulants--ISLA 5. Thromb.Haemost. 2000;83:704-708.
134. Kraaijenhagen RA, in't Anker PS, Koopman MM et al. High plasma concentration 
of factor VIIIc is a major risk factor for venous thromboembolism. 
Thromb.Haemost. 2000;83:5-9.
135. van Hylckama Vlieg A, Christiansen SC, Luddington R et al. Elevated 
endogenous thrombin potential is associated with an increased risk of a first deep 
venous thrombosis but not with the risk of recurrence. Br.J.Haematol. 
2007;138:769-774.
136. Koster T, Rosendaal FR, Reitsma PH et al. Factor VII and fibrinogen levels as 
risk factors for venous thrombosis. A case-control study of plasma levels and 
DNA polymorphisms--the Leiden Thrombophilia Study (LETS). 
Thromb.Haemost. 1994;71:719-722.
137. O'Donnell J, Tuddenham EG, Manning R et al. High prevalence of elevated factor 
VIII levels in patients referred for thrombophilia screening: role of increased 
synthesis and relationship to the acute phase reaction. Thromb.Haemost. 
1997;77:825-828.
138. Kamphuisen PW, Eikenboom JC, Vos HL et al. Increased levels of factor VIII and 
fibrinogen in patients with venous thrombosis are not caused by acute phase 
reactions. Thromb.Haemost. 1999;81:680-683.
72
139. Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and 
risk of venous thrombosis. Br.J.Haematol. 2012;157:653-663.
140. Bank I, Libourel EJ, Middeldorp S et al. Elevated levels of FVIII:C within 
families are associated with an increased risk for venous and arterial thrombosis. 
J.Thromb.Haemost. 2005;3:79-84.
141. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor 
interaction: biological, clinical and therapeutic importance. Haemophilia. 
2010;16:3-13.
142. Ryland JK, Lawrie AS, Mackie IJ, Machin SJ. Persistent high factor VIII activity 
leading to increased thrombin generation - a prospective cohort study. 
Thromb.Res. 2012;129:447-452.
143. de Mitrio V, Marino R, Scaraggi FA et al. Influence of factor VIII/von Willebrand 
complex on the activated protein C-resistance phenotype and on the risk for 
venous thromboembolism in heterozygous carriers of the factor V Leiden 
mutation. Blood Coagul.Fibrinolysis 1999;10:409-416.
144. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated 
protein C in the absence of factor V Leiden increases the risk of venous 
thrombosis. Blood 1999;93:1271-1276.
145. Christiansen SC, Lijfering WM, Naess IA et al. The relationship between body 
mass index, activated protein C resistance and risk of venous thrombosis. 
J.Thromb.Haemost. 2012;10:1761-1767.
146. Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein 
thrombosis: the Leiden Thrombophilia Study. Thromb.Haemost. 2002;87:47-51.
147. Lowe G, Woodward M, Vessey M et al. Thrombotic variables and risk of 
idiopathic venous thromboembolism in women aged 45-64 years. Relationships to 
hormone replacement therapy. Thromb.Haemost. 2000;83:530-535.
148. Zotz RB, Gerhardt A, Kluft C, Scharf RE. Venous thromboembolism during 
pregnancy is not associated with persistent elevated activated protein C (APC) 
sensitivity ratio based on the endogenous thrombin potential. Thromb.Haemost. 
2005;93:306-310.
149. Pengo V, Biasiolo A, Pegoraro C et al. Antibody profiles for the diagnosis of 
antiphospholipid syndrome. Thromb.Haemost. 2005;93:1147-1152.
150. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients 
diagnosed with antiphospholipid syndrome. J.Thromb.Haemost. 2010;8:237-242.
151. Forastiero R, Martinuzzo M, Pombo G et al. A prospective study of antibodies to 
beta2-glycoprotein I and prothrombin, and risk of thrombosis. J.Thromb.Haemost. 
2005;3:1231-1238.
73
152. de Laat B, Pengo V, Pabinger I et al. The association between circulating 
antibodies against domain I of beta2-glycoprotein I and thrombosis: an 
international multicenter study. J.Thromb.Haemost. 2009;7:1767-1773.
153. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. 
Semin.Thromb.Hemost. 2012;38:348-352.
154. Zoller B, Garcia de FP, Dahlback B. A common 4G allele in the promoter of the 
plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary 
embolism and arterial thrombosis in hereditary protein S deficiency. 
Thromb.Haemost. 1998;79:802-807.
155. Blomback B, Carlsson K, Hessel B et al. Native fibrin gel networks observed by 
3D microscopy, permeation and turbidity. Biochim.Biophys.Acta 1989;997:96-
110.
156. Carter AM, Catto AJ, Kohler HP et al. alpha-fibrinogen Thr312Ala polymorphism 
and venous thromboembolism. Blood 2000;96:1177-1179.
157. Standeven KF, Grant PJ, Carter AM et al. Functional analysis of the fibrinogen 
Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. 
Circulation 2003;107:2326-2330.
158. van Stralen KJ, Doggen CJ, Bezemer ID et al. Mechanisms of the factor V Leiden 
paradox. Arterioscler.Thromb.Vasc.Biol. 2008;28:1872-1877.
159. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein 
C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-2100.
160. Antovic JP, Blomback M. Thrombin-activatable fibrinolysis inhibitor antigen and 
TAFI activity in patients with APC resistance caused by factor V Leiden 
mutation. Thromb.Res. 2002;106:59-62.
161. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples 
the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin 
complex. J.Biol.Chem. 1996;271:16603-16608.
162. Colucci M, Simioni P, Piro D et al. An antifibrinolytic effect associated with an 
anti-factor V antibody in a patient with severe thrombophilia. Haematologica 
2003;88:1383-1389.
 
74
 
75
9. Errata 
 
76
 
77
10. Papers I-III 

I

II

III

